fda tirzepatide approval Lilly's Mounjaro receives for type 2 diabetes treatment The FDA has expanded the

It can disrupt the formation of new hair cells and prevent their proper development

However, research shows that 5080% of weight loss returns within 1 year after stopping, particularly in patients with genetic predisposition to obesity or metabolic dysfunction

The next frontier is GLP-1 pills, and so far, it looks like Novo may have an early lead once again: In clinical trials, people on the pill version of Wegovy lost an average of 16.6% of their body weight after 64 weeks, compared to Eli Lillys GLP-1 pill, Foundayo, which helped patients lose 12.4% of their body weight after 72 weeks

B., Janmohamed, S., et al